Evidence map›Paper›PMID 38329336›Full record

ArticleJournal of virology2024

Functional properties of measles virus proteins derived from a subacute sclerosing panencephalitis patient who received repeated remdesivir treatments.

Katharina S Schmitz, Kim Handrejk, Lelde Liepina, Lisa Bauer, Griffin D Haas, Fabiënne van Puijfelik, Edwin J B Veldhuis Kroeze, Marta Riekstina, Jurgis Strautmanis, Huyen Cao and 8 more

Open access · hybridAbstract readCase Reports
In one paragraph

Article in Journal of virology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Evaluation of Small-Molecule Candidates as Modulators of M-Type KInternational journal of molecular sciences · 2025
    Review
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 4 countries.

Katharina S Schmitz *Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0002-8537-0646
Kim Handrejk *Department of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
Lelde LiepinaClinic for Pediatric Neurology and Neurosurgery, Children's Clinical University Hospital, Riga, Latvia.
Lisa BauerDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0002-9461-7284
Griffin D HaasDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Fabiënne van PuijfelikDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
Edwin J B Veldhuis KroezeDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
Marta RiekstinaDepartment of Pathology, Children's Clinical University Hospital, Riga, Latvia.
Jurgis StrautmanisClinic for Pediatric Neurology and Neurosurgery, Children's Clinical University Hospital, Riga, Latvia.
Huyen CaoDepartments of Clinical Research, Biometrics, and Virology, Gilead Sciences, Inc., Foster City, California, USA.
Robert M VerdijkDepartment of Pathology, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Corine H GeurtsvanKesselDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
Sander van BoheemenDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.
Debby van RielDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0001-9753-3564
Benhur LeeDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.ORCID 0000-0003-0760-1709
Matteo PorottoDepartment of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.ORCID 0000-0003-3866-9220
Rik L de SwartDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0003-3599-8969
Rory D de VriesDepartment of Viroscience, Erasmus MC, Rotterdam, The Netherlands.ORCID 0000-0003-2817-0127
Erasmus MC · NLChildren's Clinical University Hospital · LVIcahn School of Medicine at Mount Sinai · USGilead Sciences (United States) · USUniversity of Campania "Luigi Vanvitelli" · IT

Funding

Design of fusion inhibitors to block measles host-to-host infectionR01AI176833 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Matteo Porotto · 2023 to 2026
$2.8M
Mechanisms of measles virus CNS adaptationR01NS091263 · NINDS · WEILL MEDICAL COLL OF CORNELL UNIV · PI POROTTO, MATTEO · 2015 to 2019
$1.9M
Development of therapeutic fusion inhibitor peptides for Measles encephalitisR01NS105699 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI POROTTO, MATTEO · 2018 to 2022
$1.8M
NIAID NIH HHS R01 AI176833NINDS NIH HHS R01 NS091263NINDS NIH HHS R01 NS105699
6 · The paper itself

Abstract

Subacute sclerosing panencephalitis (SSPE) is a rare but fatal late neurological complication of measles, caused by persistent measles virus (MeV) infection of the central nervous system. There are no drugs approved for the treatment of SSPE. Here, we followed the clinical progression of a 5-year-old SSPE patient after treatment with the nucleoside analog remdesivir, conducted a post-mortem evaluation of the patient's brain, and characterized the MeV detected in the brain. The quality of life of the patient transiently improved after the first two courses of remdesivir, but a third course had no further clinical effect, and the patient eventually succumbed to his condition. Post-mortem evaluation of the brain displayed histopathological changes including loss of neurons and demyelination paired with abundant presence of MeV RNA-positive cells throughout the brain. Next-generation sequencing of RNA isolated from the brain revealed a complete MeV genome with mutations that are typically detected in SSPE, characterized by a hypermutated M gene. Additional mutations were detected in the polymerase (L) gene, which were not associated with resistance to remdesivir. Functional characterization showed that mutations in the F gene led to a hyperfusogenic phenotype predominantly mediated by N465I. Additionally, recombinant wild-type-based MeV with the SSPE-F gene or the F gene with the N465I mutation was no longer lymphotropic but instead efficiently disseminated in neural cultures. Altogether, this case encourages further investigation of remdesivir as a potential treatment of SSPE and highlights the necessity to functionally understand SSPE-causing MeV.IMPORTANCEMeasles virus (MeV) causes acute, systemic disease and remains an important cause of morbidity and mortality in humans. Despite the lack of known entry receptors in the brain, MeV can persistently infect the brain causing the rare but fatal neurological disorder subacute sclerosing panencephalitis (SSPE). SSPE-causing MeVs are characterized by a hypermutated genome and a hyperfusogenic F protein that facilitates the rapid spread of MeV throughout the brain. No treatment against SSPE is available, but the nucleoside analog remdesivir was recently demonstrated to be effective against MeV

Indexed as

Adenosine MonophosphateAlanineMeaslesMeasles virusSubacute Sclerosing PanencephalitisViral ProteinsAutopsyBrainChild, PreschoolDisease ProgressionFatal OutcomeGenome, ViralHigh-Throughput Nucleotide SequencingHumansMutant ProteinsQuality of LifeAdenosine MonophosphateAlanineMutant ProteinsremdesivirRNA, ViralViral Proteinsfusionmeaslesremdesivirresistancesubacute sclerosing panencephalitis

Identifiers

PMID38329336
PMCPMC10949486
OpenAlexW4391654338

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.